
BBL/SECT/19/2025-26**Date: 8 August 2025**

To,

The Listing Department

National Stock Exchange of India Limited,

Exchange Plaza, C-1, Block G,

Bandra Kurla Complex, Bandra (E),

Mumbai - 400 051

NSE Symbol: BANKA

Dear Sir/Madam,

Sub: Outcome of Board Meeting dated 8 August 2025 and Integrated Filings (Financial)**Ref: Regulation 30 & 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").**

This is to inform you that the Board of Directors at its Meeting held today, i.e., 8 August 2025, considered and approved the following:

- 1) Unaudited standalone and consolidated financial results of the Company for the quarter and three months ended 30 June 2025, based on recommendation of Audit Committee.
- 2) Limited Review Reports (standalone and consolidated) thereon, for the quarter and three months ended 30 June 2025, based on recommendation of Audit Committee.

A copy of the aforementioned Financial Results along with the Auditors' Reports thereon pursuant to Regulation 33 of SEBI Listing Regulations are enclosed herewith.

We are also arranging to upload the aforesaid Financial Results on the Company's website at <https://www.bankabio.com/investors> and shall publish the Financial Results in the newspapers, in the format prescribed under Regulation 47 of the SEBI Listing Regulations.

- 3) Based on recommendation of Nomination and Remuneration Committee and subject to approval of members of the Company, in the ensuing Annual General Meeting, re-appointment of Mr. Sanjay Banka (DIN: 06732600) as Director, designated as Executive Chairman of the Company, who retires by rotation, *(Details provided in Annexure I)*
- 4) Based on recommendation of Nomination and Remuneration Committee and subject to approval of members of the Company, in the ensuing Annual General Meeting, re-appointment of Mr. Vishal Murarka (DIN: 06729485) as Executive Director, designated as Chief Executive Officer of the Company, for a period of 3 years, effective from 1 October 2025 to 30 September 2028 (both days inclusive). *(Details provided in Annexure I)*

- 5) Based on recommendation of Nomination and Remuneration Committee and subject to approval of members of the Company, in the ensuing Annual General Meeting, re-appointment of Dr. Basava Raju Dumpala (DIN: 03303947), who has attained the age of seventy-five years, as a Non-Executive Independent Director for a second term of five years, effective from 17 September 2025 to 16 September 2030 (both days inclusive). *(Details provided in Annexure II).*
- 6) Based on recommendation of Nomination and Remuneration Committee and subject to approval of members of the Company, in the ensuing Annual General Meeting, appointment of Mrs. Geeta Goti (DIN: 06866598) as a Non-Executive Woman Independent Director for first term of five years, effective from 17 September 2025 to 16 September 2030 (both days inclusive). *(Details provided in Annexure II)*
- 7) Approved the Board Report, along with its annexures, for the year ended 31 March 2025 along with Management Discussion and Analysis Report and Corporate Governance Report.
- 8) Approved holding of 13th Annual General Meeting of the Company on Wednesday, 10 September 2025, through video conferencing/other audio video visual means (VC/OAVM) along with approving the notice of said Annual General Meeting.
- 9) Appointment of Mr. M Ramana Reddy, (C P No. 18415), Practicing Company Secretary, as Scrutinizer for the purpose of 13th Annual General Meeting of the Company.
- 10) Took note of retirement of Mrs. Aparajita Agrawal (DIN: 08789734), Non-Executive Independent Director upon completion of her tenure as Independent Director, effective from close of business hours on 16 September 2025.

The Company places on record its sincere appreciation for the contribution made by Mrs. Aparajita Agrawal, during her tenure on the Board of the Company.

This intimation shall also be considered as Integrated Filing (Financial) for the quarter and three months ended 30 June 2025 pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 read with SEBI Circular No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated 31 December 2024, read with NSE Circular No. NSE/CML/2025/02 dated 2 January 2025.

The meeting commenced at 04:15 PM and concluded at 05:30 PM.

We request you to kindly take note of the same in your record.

Thank you,

For Banka BioLoo Limited

Nitika Lakhotia
Company Secretary & Compliance Officer

Encl: As above



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of BANKA BIOLOO LIMITED

We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter ended June 30, 2025 (the "statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 (the Circular).

1. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contain any material misstatement.

For M/s. B.D. Saboo and Associates

Chartered Accountants

Firm Registration No: 003505s

Hyderabad

ERN: 003505S

Chartered Accountants

Shyam Sunder Modani

Partner

Membership No: 213530

Place: Hyderabad

Date: 08-08-2025

UDIN: 25213530BM11VS3233

Banka BioLoo Limited

Unaudited STANDALONE statement of financial results for the quarter ended 30.06.2025

Rs In Lakhs

Sl. No	Particulars	Quarter Ended			Year Ended
		Unaudited	Audited	Unaudited	Audited
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
1	Income				
	Revenue from Operations	1255.82	1408.45	1238.75	5500.03
	Other income	105.34	0.34	18.84	38.84
	Total Income	1361.16	1408.78	1257.59	5538.87
2	Expenses				
	Cost of materials consumed	302.62	543.51	218.36	1578.61
	Changes in inventories of finished goods & work-in-progress	(8.25)	(124.82)	69.68	(43.60)
	Operating Expenses	149.74	203.69	53.81	554.67
	Employee benefits expense	737.45	762.27	701.65	2913.63
	Finance costs	59.61	67.85	67.87	269.53
	Depreciation and amortisation expense	41.52	45.79	45.11	181.95
	Other expenses	76.36	84.20	50.28	303.85
	Total expenses	1359.04	1582.48	1206.75	5758.63
3	Profit before exceptional items and tax	2.12	(173.70)	50.84	(219.76)
4	Exceptional items	-	7.39	-	719.65
5	Profit/(loss) before tax.	2.12	(181.09)	50.84	(939.41)
6	Tax expense				
	(1) Current tax	-	-	7.04	-
	(2) Taxes for earlier years	-	-	-	-
	(3) MAT Credit	-	-	-	-
	(4) Deferred tax	(11.43)	(8.18)	1.51	(9.77)
	Total Tax expense	(11.43)	(8.18)	8.55	(9.77)
7	Profit after tax	13.54	(172.90)	42.29	(929.64)
	Other comprehensive income				
	<i>Items that will not be reclassified to profit and loss</i>				
	Remeasurement of post-employment benefit obligations	-	23.86	-	23.86
	Income tax effect on items that will not be reclassified	-	(6.00)	-	(6.00)
8	Other comprehensive income for the year	-	17.85	-	17.85
9	Total comprehensive income for the year	13.54	(155.05)	42.29	(911.79)
10	Paid up equity share capital (Face value Rs. 10/- each)	1088.41	1087.42	1084.66	1087.42
11	Earnings per share				
	Basic Earnings per share (in Rs.)	0.12	(1.59)	0.39	(8.57)
	Diluted Earnings per share (in Rs.)	0.12	(1.59)	0.38	(8.57)
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

For & on behalf of board of directors

Place: Hyderabad
Date: 08.08.2025

Vishal Murarka
Vishal Murarka
CEO & Executive Director
DIN: 06729485



Notes:


1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 08 August 2025.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter ended 30 June 2025 have been prepared following the same accounting policies as those followed for the annual financial statements for the year ended 31 March 2025.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
7. During the period ended 30 June 2025, the Company has made an allotment of 9,900 equity shares of Rs. 10/- each on 20 June 2025, pursuant to exercise of vested options under Banka BioLoo Limited Employee Stock Option Plan 2023. Accordingly, the Paid-up share capital of the Company is increased from Rs. 10,87,42,070/- to Rs. 10,88,41,070/-. However, owing to pending Corporate Action with NSDL, the Company is yet to receive approval for listing and trading of the said shares from NSE. Hence, the allotment of 9,900 equity shares amounting to Rs. 99,000/- is not reflected in the records of Depository, RTA and NSE as mentioned above.
8. Figures of previous year / period have been regrouped / recast wherever necessary, to make them comparable.

For Banka BioLoo Limited

Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 08 August 2025





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

Board of Directors of **BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **BANKA BIOLOO LIMITED** (The Parent) and its subsidiary (The parent and its subsidiaries and its associate together referred to as the "Group") for the quarter ended 30 June 2025 ("the statement"), being submitted by the Parent Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the parent's management and approved by the parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended to the extent applicable.

4. The Statement includes the results of the following entities.

Holding/Parent Company

BANKA BIOLOO LIMITED

Wholly Owned Subsidiary

ENZOTECH SOLUTIONS PRIVATE LIMITED

Subsidiary

MEGALITER VARUNAA PRIVATE LIMITED

Associate

SAI BANKA SPV PRIVATE LIMITED (with a share of 50% to the holding company)



B.D. SABOO & ASSOCIATES
CHARTERED ACCOUNTANTS


Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.


Other Matter

We did not review the interim financial information of 1 subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 0 Lacs, total net loss of Rs.0.51 Lacs and total comprehensive loss of Rs. 0.51 Lacs for the quarter ended June 30, 2025, as considered in the statement. This interim financial information has not been reviewed by other auditors.

The statement also includes financial results of 1 associate as mentioned above, whose share of net profit after tax of Rs. 1.15 Lacs and total comprehensive income of Rs. 1.15 Lacs for the quarter ended June 30, 2025, as considered in the unaudited consolidated financial results, based on their interim financial results which have not been reviewed, and which has been furnished to us by the Management. According to the information and explanations given to us by the management, these unaudited interim standalone financial results are not material to the group.

For M/s. B.D. Saboo and Associates
Chartered Accountants
Firm Registration No. 003505S


Shyam Sunder Modani
Partner
Membership No. 213530



Place: Hyderabad
Date: 08-08-2025

UDIN: 25213530BM11VT1004

Banka BioLoo Limited
Unaudited CONSOLIDATED statement of financial results for the quarter ended 30.06.2025
Rs. In Lakhs

Sl. No	Particulars	Quarter Ended			Year Ended
		Unaudited	Audited	Unaudited	Audited
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
1	Income				
	Revenue from Operations	1114.12	1483.53	1288.55	5417.35
	Other income	105.34	1.79	11.33	32.78
	Total Income	1219.46	1485.32	1299.88	5450.14
2	Expenses				
	Cost of materials consumed	124.22	572.20	237.68	1553.08
	Changes in inventories of finished goods & work-in-progress	(8.25)	(124.82)	69.68	42.69
	Operating Expenses	149.74	224.21	53.81	555.10
	Employee benefits expense	737.45	762.49	701.65	2914.72
	Finance costs	89.42	102.73	87.46	376.11
	Depreciation and amortisation expense	63.84	66.45	61.84	253.08
	Other expenses	76.72	66.22	50.93	639.05
	Total expenses	1233.14	1669.48	1263.05	6333.83
3	Share of profit/(loss) of Associates	1.15	0.75	0.73	2.84
4	Profit/(loss) before tax exceptional items	(12.53)	(183.40)	37.57	(880.86)
5	Exceptional items	-	-	-	31.51
6	Profit/(loss) before tax	(12.53)	(183.40)	37.57	(912.38)
7	Tax expense				
	(1) Current tax	-	-	7.04	-
	(2) Taxes for earlier years	-	(0.64)	-	(0.64)
	(3) MAT Credit	-	-	-	-
	(4) Deferred tax	(12.74)	(21.20)	1.31	(20.87)
	Total Tax expense	(12.74)	(21.84)	8.36	(21.51)
8	Profit after tax	0.21	(161.56)	29.21	(890.87)
	Other comprehensive income				
	<i>Items that will not be reclassified to profit and loss</i>				
	Remeasurement of post-employment benefit obligations	-	23.86	-	23.86
	Income tax effect on items that will not be reclassified	-	(6.00)	-	(6.00)
9	Other comprehensive income for the year	-	17.85	-	17.85
10	Total comprehensive income for the year	0.21	(143.71)	29.21	(873.01)
	Attributable to				
	Shareholders of the Company	0.51	(144.64)	29.31	(873.66)
	Non controlling interest	(0.30)	0.93	(0.09)	0.64
11	Paid up equity share capital (Face value Rs. 10/- each)	1088.41	1087.42	1084.66	1087.42
12	Earnings per share				
	Basic Earnings per share (in Rs.)	0.00	(1.50)	0.27	(8.21)
	Diluted Earnings per share (in Rs.)	0.00	(1.50)	0.27	(8.21)
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

For & on behalf of board of directors

Vishal Murarka
 CEO & Executive Director
 DIN: 06729485

Place: Hyderabad
Date: 08.08.2025


Notes:

1. The above statement of unaudited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 08 August 2025.
2. The Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Megaliter Varunaa Pvt Ltd	Subsidiary
Sai Banka SPV Pvt Ltd	Associate with 50% share to the Company

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Consolidated Financial Results for the quarter ended 30 June 2025 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31 March 2025.
6. Based on the internal reporting provided to the Chief Operating Decision Maker, the consolidated financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
7. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
8. During the period ended 30 June 2025, the Company has made an allotment of 9,900 equity shares of Rs. 10/- each on 20 June 2025, pursuant to exercise of vested options under Banka BioLoo Limited Employee Stock Option Plan 2023. Accordingly, the Paid-up share capital of the Company is increased from Rs. 10,87,42,070/- to Rs. 10,88,41,070/-. However, owing to pending Corporate Action with NSDL, the Company is yet to receive approval for listing and trading of the said shares from NSE. Hence, the allotment of 9,900 equity shares amounting to Rs. 99,000/- is not reflected in the records of Depository, RTA and NSE as mentioned above.
9. Figures of previous year / period have been regrouped / recast wherever necessary, to make them comparable.

For Banka BioLoo Limited

Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485

Place: Hyderabad
Date: 08 August 2025



B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE QUALIFIED INSTITUTIONS PLACEMENT ETC.

- Not Applicable for this quarter

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES.

- Not Applicable for this quarter

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

- Not Applicable for this quarter

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

- Not Applicable for this quarter

Annexure I

Details as required under Regulation 30 of the SEBI Listing Regulations read with clause 7 of Para A of Part A of Schedule III and SEBI Master Circular dated November 11, 2024, as amended from time to time

Particulars	Mr. Sanjay Banka	Mr. Vishal Murarka
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Sanjay Banka, Director, designated as Executive Chairman of the Company, who retires by rotation.	Re-appointment of Mr. Vishal Murarka as Executive Director, designated as Chief Executive Officer of the Company.
Date of appointment & Terms of appointment	<p><u>Date of Re-appointment:</u> With effect from ensuing Annual General Meeting</p> <p><u>Terms of Re-appointment:</u> Reappointment of Mr. Sanjay Banka, Director, designated as Executive Chairman of the Company, who retires by rotation, subject to the approval of members in the ensuing Annual General Meeting.</p>	<p><u>Date of Re-appointment:</u> With effect from 1 October 2025</p> <p><u>Terms of Re-appointment:</u> Reappointment of Mr. Vishal Murarka as Executive Director, designated as Chief Executive Officer of the Company, for a period of 3 years, effective from 1 October 2025 to 30 September 2028 (both days inclusive), subject to the approval of members in the ensuing Annual General Meeting.</p>
Brief Profile	Mr. Sanjay Banka, aged 55 years, is the Executive Chairman of the Company. He holds degree in Bachelor of Arts from Mumbai University, Bachelor of General Law from Veer Narmad South Gujarat University and Master of Business Administration from Stuttgart Institute of Management and Technology, Germany. He has more than two decades of experience working in senior positions with MNCs, in areas of financial services, business and industry research on global companies across industries. His functional responsibility is developing industry networks for further business development, building national and international partnerships and collaborations, fund raising - nationally and globally, advocacy on water, sanitation and hygiene (WaSH).	Mr. Vishal Murarka, is the Executive Director and Chief Executive Director of the Company. He holds degree in MBA in Marketing & Finance from the Indian School of Business and Undergraduate degree in engineering. He has over 20 years of rich and varied experience covering a range of industries across technology, infrastructure and real-estate. He collaborated in multilingual environment across markets in Asia, Europe and the US. Prior to Banka BioLoo, he was associated with a French MNC in South Korea, TATA Group, Larsen & Toubro and Piramal group in multiple leadership positions. His functional responsibility lies in leadership and general management, strategic and business planning, corporate governance, risk and compliance, stakeholder engagement, financial and fund raising.

Disclosure of relationships between directors (in case of appointment of a director)	<ul style="list-style-type: none"> • Mrs. Namita Sanjay Banka (Managing Director): Spouse • Mr. Vishal Murarka (Executive Director & Chief Executive Officer): Brother-in-law <p>Except as stated above, Mr. Sanjay Banka is not related to any other Director.</p>	<ul style="list-style-type: none"> • Mrs. Namita Sanjay Banka (Managing Director): Sister • Mr. Sanjay Banka (Executive Chairman): Brother-in-law <p>Except as stated above, Mr. Vishal Murarka is not related to any other Director.</p>
Information as required pursuant to NSE Circular Ref. No. SE/CML/2018/24 dated June 20, 2018	Mr. Sanjay Banka is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.	Mr. Vishal Murarka is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.

Annexure II

Details as required under Regulation 30 of the SEBI Listing Regulations read with clause 7 of Para A of Part A of Schedule III and SEBI Master Circular dated November 11, 2024, as amended from time to time

Particulars	Dr. Basava Raju Dumpala	Mrs. Geeta Goti
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Dr. Basava Raju Dumpala, who has attained the age of seventy-five years, as a Non-Executive Independent Director for a second term of five years.	Re-appointment of Mr. Vishal Murarka as Executive Director, designated as Chief Executive Officer of the Company.
Date of appointment & Terms of appointment	<p><u>Date of Re-appointment:</u> With effect from 17 September 2025</p> <p><u>Terms of Re-appointment:</u> Reappointment of Dr. Basava Raju Dumpala, who has attained the age of seventy-five years, as a Non-Executive Independent Director for a second term of five years, effective from 17 September 2025 to 16 September 2030 (both days inclusive), subject to the approval of members in the ensuing Annual General Meeting.</p>	<p><u>Date of Appointment:</u> With effect from 17 September 2025</p> <p><u>Terms of Appointment:</u> Appointment of Mrs. Geeta Goti, as a Non-Executive Woman Independent Director for a first term of five years, effective from 17 September 2025 to 16 September 2030 (both days inclusive), subject to the approval of members in the ensuing Annual General Meeting.</p>
Brief Profile	Dr. Basava Raju Dumpala is currently serving as a Non-Executive Independent Director of the Company. He is a senior management professional who combines corporate leadership experience with an understanding of interpersonal dynamics. He has over 40 years' experience with Larsen & Toubro (L&T). As a member of the top management team of L&T, Dr. Raju helmed several key business and corporate functions. He was the Executive Vice President and Advisor to the Chairman, L&T. Among the business roles, Dr. Raju handled several sales and marketing functions, taught Industrial Marketing at National Institute of Industrial Engineering and S P Jain Institute of Management and Research, Mumbai. Dr. Raju's rich diversity of experience gave him a	Mrs. Geeta Goti is a well-known name in HR Consulting, Corporate Governance and Labour Compliance. Her consulting experience is across various companies dealing with agriculture, airlines, FMCG, Banking, IT services and NGOs in countries like US, UAE, Mexico, China, Sri Lanka and extensively travelled in India. She is one of the few professionals worked since year 2000 on Prevention of Sexual Harassment of Women at Workplace under the Vishaka Guidelines directed by Supreme Court much before the Act was passed in 2013. Her academic qualifications include MSW (Masters in Social Work, 1988), Bachelor degree in Law (1992), has been associated with NHRD Hyderabad chapter as Life member; and as Secretary in 2000. She is nominated by Government of India as first Woman Independent

	ring-side view of the top management and enabled him to acquire a thorough understanding of the leadership psyche. He has coached and mentored several senior executives from manufacturing, infrastructure, technology, finance and realty sectors.	Director on the Board of National Small Industries Corporation Limited (2017-2020), a Public Sector Enterprise under Ministry of MSME. She was associated to our Company as an Independent Director from 2017 till 2020.
Disclosure of relationships between directors (in case of appointment of a director)	NIL	NIL
Information as required pursuant to NSE Circular Ref. No. SE/CML/2018/24 dated June 20, 2018	Dr. Basava Raju Dumpala is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.	Mrs. Geeta Goti is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.